Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001615774-19-008232
Filing Date
2019-05-22
Accepted
2019-05-22 13:48:02
Documents
69
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q s117859_10q.htm 10-Q 1023055
2 EXHIBIT 31.1 s117859_ex31-1.htm EX-31.1 8455
3 EXHIBIT 31.2 s117859_ex31-2.htm EX-31.2 8230
4 EXHIBIT 32.1 s117859_ex32-1.htm EX-32.1 5096
5 EXHIBIT 32.2 s117859_ex32-2.htm EX-32.2 5866
  Complete submission text file 0001615774-19-008232.txt   4960826

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE nspx-20180331.xml EX-101.INS 1056506
7 XBRL SCHEMA FILE nspx-20180331.xsd EX-101.SCH 40667
8 XBRL CALCULATION FILE nspx-20180331_cal.xml EX-101.CAL 45953
9 XBRL DEFINITION FILE nspx-20180331_def.xml EX-101.DEF 201546
10 XBRL LABEL FILE nspx-20180331_lab.xml EX-101.LAB 305063
11 XBRL PRESENTATION FILE nspx-20180331_pre.xml EX-101.PRE 282933
Mailing Address 2511 N LOOP 1604 W SUITE 204 SAN ANTONIO TX 78258
Business Address 2511 N LOOP 1604 W SUITE 204 SAN ANTONIO TX 78258 (210) 479-8112
Inspyr Therapeutics, Inc. (Filer) CIK: 0001421204 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55331 | Film No.: 19845057
SIC: 2834 Pharmaceutical Preparations